Status: Recruiting
Post Marketing Observational Study on Safety of BALFAXAR vs. KCENTRA for Reversal of Vitamin K Antagonist Induced Anticoagulation in Adults Undergoing Urgent Surgery or Invasive Procedure
Post marketing observational study on safety of BALFAXAR vs. KCENTRA for Reversal of Vitamin K Antagonist Induced Anticoagulation in Adults Undergoing Urgent Surgery or Invasive Procedure
Participants needed: 3,574
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: OctapharmaUpdated: Jun 4, 2025Locations: 1
Eligibility criteria
Subjects at least 18 years of age. [+2]
History of TEE within 90 days before receipt of VKA reversal therapy. [+1]